David A. Siegel Ascendis Pharma A/S Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Two Sigma Advisers, LP holds 163,400 shares of ASND stock, worth $22.3 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
163,400Holding current value
$22.3 Million% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
211Shares Held
46.5MCall Options Held
310KPut Options Held
306K-
Artisan Partners Limited Partnership Milwaukee, WI5.67MShares$774 Million1.32% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.08MShares$556 Million3.29% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.97MShares$541 Million7.23% of portfolio
-
Janus Henderson Group PLC London, X03.77MShares$514 Million0.32% of portfolio
-
Wellington Management Group LLP Boston, MA2.75MShares$374 Million0.08% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.61B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...